Built with Ventus Therapeutics, Inflammasome Therapeutics, Merck and more, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof-of-concept clinical trials and beyond!
With a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021, this year's summit will once again unite thought leaders in inflammasome drug development.
Expect to be involved in interactive discussions on:
- How dysregulated inflammasome activation, formation and signaling contributes to disease and how to identify novel drug targets beyond NLRP3
- The interface of inflammasome signaling with innate immunity, microbial interactions, metabolism, neuroimmune and other systems
- Leveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting
- Identifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases, as well as infectious, ophthalmic, neurological and cancer settings
This year's meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and, commercial potential of inflammasome proteins across different diseases!
Running digitally November 16-18, 2021.
Group discounts and early booking rates are available. Please visit the website for full pricing information.
Time: 9:00 am - 5:00 pm
Conference + 1 Workshop (Industry): USD 2498.00,
Conference Only (Industry): USD 2099.00,
Conference + 1 Workshop (Academic): USD 1698.00,
Conference Only (Academic): USD 1499.00,
Conference + 1 Workshop (Service Provider): USD 3098.00,
Conference Only (Service Provider): USD 2599.00
Speakers: Adam Schwaid, Associate Principal Scientist, Merck and Co., Inc., Ali Jazayeri, Chief Scientific Officer, OMass Therapeutics, Andrea Kwakowsky, Senior Research Fellow, University of Auckland, Anil K. Goyal, CEO and Chairperson, IMMvention Therapeutix, Inc., Ashley Mansell, Senior Director of Research and Development/Principal Investigator, Bacainn Therapeutics/Hudson Institute of Medical Research, Colin R. Green, Professor/Chief Scientist University of Auckland/OcuNexus Therapeutics, Inc. and InflammX Therapeutics, Inc., David J. Bearss, CSO and President, Halia Therapeutics, Inc, Donald F. Weaver, Director, Krembil Research Institute, Elsa Sanchez- Lopez, Assistant Professor, University of California San Diego, Department of Orthopedic Surgery, Hal Hoffman, Professor and Chief, Division of Pediatric Allergy, Immunology, Rheumatology University of California at San Diego and Rady Children’s Hospital, Hao Wu, Professor, Boston Children’s Hospital and Harvard Medical School, Humayun Sharif, Instructor, Harvard Medical School, James D. Thacker, Founder, Head of Discovery and Science Therimunex Pharmaceuticals, Inc., Johannes Grosse, Sr. Director Pharmacology, VIR Biotechnology, Juan Pablo de Rivero Vaccari, Research Associate Professor of Neurological Surgery and The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Karen Cashmere, Chief Commercial Officer, Zyversa Therapeutics, Inc., Kate Schroder, Head, Inflammasome Lab and Director IMB Centre for Inflammation and Disease Research, The University of Queensland, Liang Shan, Assistant Professor, Washington University in St. Louis, Marie Kosco Vilbois, Chief Scientific Officer, AC Immune SA, Martha O’Brien, Senior Research Scientist, Promega, Michael Crackower, Chief Scientific Officer, Ventus Therapeutics, Pablo Pelegrin, Scientific Deputy Director Biomedical Research Institute of Murcia, University of Murcia, Paul Ashton, President and CEO, Inflammasome Therapeutics, Inc., Rebecca Coll, Lecturer in Immunobiology and Principal Investigator Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Robert W. Keane, Professor, University of Miami Miller School of Medicine, Rugmani Iyer, Senior Scientist, Merck and Co., Inc., Seung-Yong Seong, Professor, Department of Microbiology and Immunology and Co- CEO, Shaperon Inc., Steve Glover, Co-Founder, Chief Executive Officer and Chairman, Zyversa Therapeutics, Inc., Sunhwa Kim, Principal Scientist, Merck Research Institute, Vishal Singh, Assistant Professor, Pennsylvania State University